GlycoMimetics, Inc.(GLYC)

Description: GlycoMimetics, Inc., a clinical stage biotechnology company, focuses on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases. Its lead product includes GMI-1070, a glycomimetic drug candidate that acts as a pan-selectin antagonist has completed Phase II clinical trials for the treatment of vaso-occlusive crisis, a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease. The company is also developing GMI-1271, a specific E-selectin antagonist, which it plans to initiate a Phase I dose-escalation clinical trials in healthy volunteers to be used in combination with chemotherapy to treat acute myeloid leukemia and potentially other hematologic cancers. In addition, its drug candidates comprise GMI-1051 and other drug candidates for pseudomonas virulence factors. The company has a collaborative research and development agreement with Pfizer Inc. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Gaithersburg, Maryland.

---

Keywords: Biotechnology Disease Drug Discovery Clinical Trial Chemotherapy Acute Myeloid Leukemia Product Testing Pseudomonas Sickle Cell Disease Hematologic Cancers Nursing Research

---

Home Page: www.glycomimetics.com

GLYC Technical Analysis

9708 Medical Center Drive
Rockville, MD 20850
United States
Phone: 240 243 1201

---

Officers

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)